4-(1H-吡唑-3-基)苯胺 | 89260-45-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-(1H-吡唑-3-基)苯胺
• 中文别名: 4-(1H-3-吡唑基)苯胺盐酸盐
• 英文名称: 5-(4-aminophenyl)-1H-pyrazole
• 英文别名: 1-(4-aminophenyl)pyrazole；5-(4-aminophenyl)pyrazole；3-(4-Aminophenyl)pyrazole；4-(1H-pyrazol-5-yl)aniline
• CAS: 89260-45-7
• 化学式: C₉H₉N₃
• mdl: MFCD03094636
• 分子量: 159.191
• InChiKey: WGZDTRWVJYXEFO-UHFFFAOYSA-N

物化性质

• 熔点：
  110-115°C
• 沸点：
  396.8±17.0 °C(Predicted)
• 密度：
  1.238

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.7
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933199090
• WGK Germany：
  3
• 储存条件：
  存储条件：室温、干燥、避光、惰性气体环境。

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 3-(4-Aminophenyl)pyrazole
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 89260-45-7
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
The product does not need to be labelled in accordance with EC directives or respective national laws.
Other hazards
Possible sensitizer.

---

SECTION 3: Composition/information on ingredients
Substances
Formula : C9H9N3
Molecular Weight : 159,19 g/mol
CAS-No. : 89260-45-7
No components need to be disclosed according to the applicable regulations.

---

SECTION 4: First aid measures
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapours, mist or gas.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Handle and store under inert gas. Heat-, light-, and moisture-sensitive.
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing 110 - 115 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Further information
Copyright 2013 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  4-(1H-吡唑-3-基)苯胺 在 碘 、 n-butyltriphenylphosphonium peroxodisulfate 作用下， 以 水 、 乙腈 为溶剂， 反应 1.0h， 以90%的产率得到3-(4-amino phenyl)-4-iodo-1H-pyrazole
  参考文献：
  名称：

  Mild regioselective iodination of pyrazoles using n-butyltriphenylphosphonium peroxodisulfate

  摘要：

  A practical, efficient and inexpensive method of synthesis of iodopyrazoles by the reaction of pyrazoles with iodine using n-butyltriphenylphosphonium peroxodisulfate as an oxidant at room temperature is reported. The use of n-butyltriphenylphosphonium peroxodisulfate is feasible due to its easy preparation and handling, high stability and activity.

  DOI：

  10.1134/s1070363216080259
• 作为产物：
  描述：

  1-(4-nitrophenyl)-3-N,N-dimethylamino-2-propen-1-one 在 palladium 10% on activated carbon 、 氢气 、 一水合肼 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 为溶剂， 反应 13.5h， 生成 4-(1H-吡唑-3-基)苯胺
  参考文献：
  名称：

  一种苯丙酰胺类杀虫剂及其制备方法

  摘要：

  本发明涉及有机合成及应用技术领域，具体涉及一种苯丙酰胺类杀虫剂及其制备方法，所述苯丙酰胺类杀虫剂以苯丙氨酸和取代苯乙酸等为原料，经过加成、成环、还原和酰胺化等反应，得到的苯丙酰胺类杀虫剂结构通式如下：本发明合成条件温和，操作简便安全，各步反应得率高，后处理方式简单；本发明的氨苯丙酰胺类杀虫剂有效防治水产养殖的病虫害，提高鱼类等养殖品种的质量和成活率的同时，不会对养殖池生态环境造成危害，安全性高。

  公开号：

  CN107488148A

文献信息

• Synthesis and characterization of the first inhibitor of<i>N</i>-acylphosphatidylethanolamine phospholipase D (NAPE-PLD)
  作者：Beatrice Castellani、Eleonora Diamanti、Daniela Pizzirani、Piero Tardia、Martina Maccesi、Natalia Realini、Paola Magotti、Gianpiero Garau、Thomas Bakkum、Silvia Rivara、Marco Mor、Daniele Piomelli

  DOI：10.1039/c7cc07582k

  日期：——

  (NAPE-PLD) is a membrane-associated zinc enzyme that catalyzes the hydrolysis of N-acylphosphatidylethanolamines (NAPEs) into fatty acid ethanolamides (FAEs). Here, we describe the identification of the first small-molecule NAPE-PLD inhibitor, the quinazoline sulfonamide derivative 2,4-dioxo-N-[4-(4-pyridyl)phenyl]-1H-quinazoline-6-sulfonamide, ARN19874.

  Ñ -Acylphosphatidylethanolamine磷脂酶d（NAPE-PLD）是一种膜相关的，其催化水解酶锌Ñ -acylphosphatidylethanolamines（NAPEs）转换成脂肪酸乙醇酰胺（的FAE）。在这里，我们描述了第一个小分子NAPE-PLD抑制剂，喹唑啉磺酰胺衍生物2,4-二氧代-N- [4-（4-吡啶基）苯基] -1 H-喹唑啉-6-磺酰胺，ARN19874的鉴定。
• [EN] SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT<br/>[FR] COMPOSÉS CYCLOPROPYLE SUBSTITUÉS, COMPOSITIONS CONTENANT DE TELS COMPOSÉS ET PROCÉDÉS DE TRAITEMENT
  申请人：MERCK SHARP & DOHME

  公开号：WO2011019538A1

  公开（公告）日：2011-02-17

  Substituted cyclopropyl compounds of the formula I: are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119.

  取代的环丙基化合物公式I：被披露为用于治疗或预防2型糖尿病和类似病症的有用物质。药物可接受的盐也包括在内。这些化合物作为G蛋白偶联受体GPR-119的激动剂是有用的。
• [EN] EXO-AZA SPIRO INHIBITORS OF MENIN-MLL INTERACTION<br/>[FR] INHIBITEURS SPIRO EXO-AZA DE L'INTERACTION MÉNINE-MLL
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2019120209A1

  公开（公告）日：2019-06-27

  Provided are compounds of Formula (I), pharmaceutical compositions comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.

  提供的是式（I）的化合物，包括这些化合物的药物组合物，以及它们作为menin/MLL蛋白质/蛋白质相互作用抑制剂的用途，用于治疗癌症、骨髓增生异常综合征（MDS）和糖尿病等疾病。
• Substituted heterocyclyl-phenylformamidines and salts thereof
  申请人：Istituto de Angeli S.p.A.

  公开号：US04699915A1

  公开（公告）日：1987-10-13

  Compounds of the formula ##STR1## wherein R is hydrogen or methyl; R.sub.1 is straight or branched alkyl of 1 to 6 carbon atoms, hydroxy(alkyl of 1 to 6 carbon atoms), mono- or di-(alkoxy of 1 to 6 carbon atoms)(alkyl of 1 to 6 carbon atoms), (alkyl of 1 to 6 cabon atoms)thio(alkyl of 1 to 6 carbon atoms), cyano(alkyl of 1 to 6 carbon atoms), alkenyl, alkynyl, or cycloalkyl; R.sub.2 is hydrogen, alkyl of 1 to 3 carbon atoms, alkoxy of 1 to 3 carbon atoms or halogen; and X is pyrazol-3-yl, 1,2,4-triazol-3-yl, pyridin-2-yl, pyridin-3-yl, thiazol-4-yl, 2-methyl-thiazol-4-yl or 2-methylamino-thiazol-4-yl; tautomers thereof, and non-toxic, pharmacologiically acceptable acid addition salts thereof. The compounds as well as their salts are useful as antiulcerogenics and gastric acid secretion inhibitors.

  式##STR1##中的化合物，其中R是氢或甲基；R.sub.1是1至6个碳原子的直链或支链烷基，羟基（1至6个碳原子的烷基），单或双（1至6个碳原子的烷氧基）（1至6个碳原子的烷基），（1至6个碳原子的烷基）硫（1至6个碳原子的烷基），氰基（1至6个碳原子的烷基），烯基，炔基或环烷基；R.sub.2是氢，1至3个碳原子的烷基，1至3个碳原子的烷氧基或卤素；X是吡唑-3-基，1,2,4-三唑-3-基，吡啶-2-基，吡啶-3-基，噻唑-4-基，2-甲基噻唑-4-基或2-甲氨基噻唑-4-基；它们的互变异构体，以及非毒性、药理学上可接受的酸盐。这些化合物及其盐可用作抗溃疡剂和胃酸分泌抑制剂。
• Phenylazole compounds, process for producing the same and drugs for hyperlipemia
  申请人：Nippon Soda Co., Ltd.

  公开号：US06342516B1

  公开（公告）日：2002-01-29

  Phenylazole compounds represented by general formula (1) or pharmaceutically acceptable salts thereof and drugs for hyperlipemia which contain these compounds as the active ingredient, wherein A represents imidazolyl, pyrazolyl, etc.; B represents (1a) or (1b) (wherein R2 and R3 represent each hydrogen, C1-6 alkyl, etc; and k is 0 or an integer of 1 to 15); Y represents O, S, a bond, etc.; and Z represents an optionally substituted and saturated or unsaturated heterocycle containing 1 to 4 N, O or S atoms. Among all, compounds wherein Z is substituted chroman-2-yl, 2,3-dihydrobenzofuran-2-yl, etc. have an effect of inhibiting the formation of lipid peroxides too.

  通用公式（1）所代表的苯唑化合物或其药用盐，以及作为活性成分含有这些化合物的高脂血症药物，其中A代表咪唑基，吡唑基等；B代表（1a）或（1b）（其中R2和R3分别代表氢，C1-6烷基等；k为0或1至15的整数）；Y代表O，S，键等；Z代表含有1至4个N、O或S原子的可选择取代的饱和或不饱和杂环。在所有化合物中，其中Z为取代的色甘酮-2-基，2,3-二氢苯并呋喃-2-基等，也具有抑制脂质过氧化物形成的作用。